A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S T | U | V | W | X | Y | Z
Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.
Key Word / Drug Name | Issue #: Page # |
A | |
| abametapir | 5:12 |
| ABP 798 | 2:12 |
| Abrilada™ | 1:8; 2:10,11 |
| acne | 5:12 |
| actinic keratosis | 5:8-9 |
| Aczone® | 2:10 |
| adalimumab | 1:8; 2:10,11; 4:12 |
| afamelanotide | 2:10 |
| AGLE-102 | 5:12 |
| Aklief® | 1:8; 2:1-2 |
| alopecia areata | 3:10; 4:6-11 |
| Amzeeq™ | 1:8; 2:10 |
| androgen receptor inhibitor | 5:12 |
| anesthetic (topical) | 1:8 |
| anti-aging | 2:3-9,10 |
| anti-cancer | 2:10; 4:9,12; 5:5, 8-12 |
| antineoplastic | 5:12 |
| antioxidants | 2:3-9 |
| anti-wrinkle | 2:3-9,10 |
| apical sodium-dependent bile acid transporter | 1:8 |
| apremilast | 2:10 |
| Arazlo™ | 2:10,12 |
| ART-12 | 4:12 |
| atezolizumab | 5:12 |
| atopic dermatitis | 1:8; 2-10; 3:10; 4:6-12 |
| autoimmune disease | 3:5-9; 4:8-9; 5:8-11 |
| Avsola™ | 1:8; 2:11; 3:10 |
B | |
| baricitinib | 3:10; 4:6-11 |
| basal cell carcinoma | 5:8-11,12 |
| Behçet’s disease | 2:10 |
| belimumab | 2:11 |
| Benlysta® | 2:11 |
| betamethasone dipropionate | 2:11; 5:12 |
| biologic | 1:8; 2:10,11; 3:1-4,10; 4:12; 5:12 |
| biosimilar | 1:8;2:10-12; 4:12 |
| blistering disorder | 5:12 |
| BMS-986165 | 4:7 |
| botulinumtoxin type A | 2:10 |
| BRAF kinase inhibitor | 5:12 |
| bullous pemphigoid | 4:8-12; 5:8-11 |
C | |
| calcipotriene | 2:11; 5:12 |
| carbon dioxide laser | 4:2-3 |
| CD-directed cytolytic antibody | 2:10 |
| celiac disease | 5:1-7 |
| cellulite | 4:12 |
| cetirizine hydrochloride | 1:8; 2:11 |
| chemoprevention | 5:8-11 |
| clascoterone | 5:12 |
| collagenase clostridium histolyticum | 4:12 |
| comorbidities | 5:1-7 |
| cortexolone 17α-propionate | 5:12 |
| corticosteroid | 2:11; 5:12 |
| Cotellic® | 5:12 |
| crisaborole | 3:10 |
| cryoglobulinemic vasculitis | 3:5-9 |
| cryotherapy | 4:2 |
| cyclophosphamide | 3:7 |
| cytotoxic agent | 3:7 |
D | |
| dapsone | 2:10 |
| dermal filler | 2:10 |
| dermatosis papulose nigra | 4:1-5 |
| diabetes | 5:1-7 |
| diet & skin aging | 2:3-9 |
| diode laser | 4:2 |
| doxycycline | 5:11 |
| Duobrii™ | 2:11; 5:12 |
| dupilumab | 2:10; 4:12 |
| Dupixent® | 2:10; 4:12 |
| dyslipidemia | 5:3-4 |
| dystrophic epidermolysis bullosa | 5:12 |
E | |
| eczema | 1:8; 2:10; 3:10; 4:6-12 |
| electrodessication | 4:2 |
| Enbrel® | 2:11 |
| Enstilar® | 2:11 |
| eosinophilic granulomatosis with polyangiitis | 3:5-9 |
| epithelial tumors | 1:1-4 |
| epithelioid sarcoma | 2:10,12 |
| ER-004 | 4:12 |
| erbium-doped fractionated laser | 4:1-5 |
| erythropoietic protoporphyria | 2:10 |
| Eskata™ | 1:1-4 |
| etanercept | 2:11 |
| Eticovo™ | 2:11 |
| Eucrisa® | 3:10 |
| excision | 4:1-2 |
| extracellular matrix (ECM) | 2:4; 5:12 |
| extracellular vesicle therapy | 5:12 |
F | |
| filaggrin gene | 1:5 |
| filgotinib | 4:7 |
| foods impacting MMPs | 2:3-9 |
G | |
| gastrointestinal disease | 5:5 |
| gene therapy | 5:12 |
| genetic counseling | 1:6 |
| glucocorticoids | 3:7 |
| glycation | 2:3-9 |
| golimumab | 5:12 |
| graft-versus-host disease | 2:10 |
| granulomatosis with polyangiitis | 2:10; 3:5-9 |
| guselkukmab | 4:12 |
| gut microbiome | 2:5,7 |
H | |
| Hadlima™ | 2:11 |
| hair loss | 3:10 |
| halobetasol propionate | 2:11 |
| hedgehog pathway inhibitor | 5:12 |
| hidradenitis suppurativa | 4:7,9 |
| histamine-1 receptor antagonist | 1:8; 2:11 |
| HP40 | 1:1-4 |
| Hulio® | 4:12 |
| Humira® | 2:10,11 |
| hyaluronic acid | 2:10 |
| hydrogen peroxide topical solution | 1:1-4 |
| hyperglycemia | 2:5 |
| hypertension | 5:3-4 |
I | |
| ichthyosis | 1:5-7 |
| immunoglobulin A vasculitis | 3:5-9 |
| immunotherapy | 2:10; 5:12 |
| infection | 4:9 |
| INCB54707 | 4:7 |
| inflammation | 2:3-9,10; 3:5-9 |
| inflammatory bowel disease | 5:1-7 |
| infliximab | 1:8; 2:11; 3:10 |
| interleukin-12 | 5:12 |
| interleukin-13 | 2:10 |
| interleukin-23 | 2:11; 3:1-4; 4:12; 5:12 |
| interleukin-4 | 2:10; 4:12 |
| itacitinib | 4:7 |
J | |
| Jakafi® | 2:10 |
| jakinibs | 4:6-11 |
| Janus kinase (JAK) inhibitor | 2:10; 3:10; 4:6-11 |
| Jeuveau™ | 2:10 |
| Juvéderm Voluma® XC | 2:10 |
| Jynneos™ | 2:11 |
K | |
| keratinization disorder | 1:5-7 |
| Keytruda® | 2:10; 4:12 |
| Koselugo® | 3:10; 4:12 |
| KTP laser | 4:1-5 |
L | |
| laser | 4:1-5 |
| lebrikizumab | 1:8 |
| lice | 5:12 |
| lichen planus pilaris | 4:9 |
| lidocaine | 1:8 |
M | |
| malignancy | 2:10; 4:9,12; 5:5 |
| maralixibat | 1:8 |
| matrix metalloproteinase (MMP) | 2:3-9 |
| MEK | 3:10; 4:12; 5:12 |
| melanocortin 1 receptor agonist | 2:10 |
| melanoma | 2:10; 4:12; 5:12 |
| Merkel cell carcinoma | 2:10 |
| metabolic syndrome | 5:1-7 |
| methotrexate | 1:8; 3:7 |
| microbiome | 4:12 |
| microscopic polyangiitis | 3:5-9 |
| minocycline | 1:8; 2:10; 4:12 |
| mitogen-activated protein kinase | 3:10; 4:12; 5:12 |
| monkey pox vaccine | 2:11 |
| monoclonal antibody | 1:8; 2:10,11; 3:1-4,10; 4:12 |
N | |
| Nd:YAG laser | 4:1-5 |
| Netherton syndrome | 4:12 |
| neurofibromatosis type 1 | 3:10; 4:12 |
| neurotoxin | 2:10 |
| niacinamide | 5:8-11 |
| nicotinamide | 5:8-11 |
| non-alcoholic fatty liver disease | 5:3-4 |
| non-melanoma skin cancer | 5:8-11 |
| nutrient supplementation | 2:6-7 |
| nutrition | 2:3-9 |
O | |
| obesity | 5:1-7 |
| Odomzo® | 5:12 |
| Olumiant® | 3:10 |
| Otezla® | 2:10 |
| oxidation | 2:3-9 |
P | |
| PD-1 inhibitor | 2:10; 4:12; 5:12 |
| pediatric psoriasis | 5:1-7 |
| pediculicide | 5:12 |
| pegylated interferon alpha | 3:7 |
| pembrolizumab | 2:10; 4:12 |
| PF-04965842 | 4:7 |
| PF-06651600 | 4:7 |
| PF-06700841 | 4:7 |
| phototoxicity | 2:10 |
| picosecond laser | 4:2 |
| plasma exchange | 3:7 |
| Pliaglis® | 1:8 |
| polycystic ovarian syndrome | 5:3 |
| prabotulinumtoxinA | 2:10 |
| primary vasculiltis | 3:5-9 |
| programmed cell death 1 inhibitor | 2:10; 4:12 |
| protein replacement therapy | 4:12 |
| pruritus | 1:8 |
| psoriasis | 1:8; 2:10,11; 3:1-4,10; 4:6-8,12; 5:1-7,12 |
| psoriatic arthritis | 1:8; 2:10,11; 3:10; 4:12; 5:1-7,12 |
| psychiatric disturbances | 5:4 |
| pruritus | 4:1-5 |
Q | |
| Q-switched laser | 4:3 |
| quality of life | 5:1-7 |
| Quzyttir™ | 1:8; 2:11 |
| Qwo™ | 4:12 |
R | |
| Remicade® | 1:8; 2:11; 3:10 |
| Retinoic acid receptor gamma | 1:8; 2:1-2 |
| retinoid | 1:6,8; 2:1-2,10-12; 5:12 |
| risankizumab | 2:11; 3:1-4 |
| Rituxan® | 2:10 |
| rituximab | 2:10,12; 3:7 |
| rosacea | 4:12 |
| ruxolitinib | 2:10; 4:6-11 |
S | |
| Scenesse® | 2:10 |
| seborrheic keratosis | 1:1-4 |
| secondary vasculitis | 3:6 |
| selumetinib | 3:10; 4:12 |
| Simponi®Aria™ | 5:12 |
| skin aging | 2:3-9 |
| skin of color | 4:1-5 |
| Skyrizi™ | 2:11 |
| smallpox vaccine | 2:11 |
| small-vessel vasculitis (primary) | 3:5-9 |
| sonidegib | 5:12 |
| squamous cell carcinoma | 4:12; 5:8-11 |
| Staphylococcus epidermidis | 4:12 |
| Stelara® | 5:12 |
| systemic lupus erythematosus | 2:11; 4:6-11 |
T | |
| Taclonex® | 2:11 |
| tazarotene | 2:10,11,12 |
| tazemetostat | 2:10,12 |
| Tazverik™ | 2:10,12 |
| Tecentriq® | 5:12 |
| tetracaine | 1:8 |
| tetracycline | 5:11 |
| thromboembolism | 4:9-10 |
| TNF-alpha | 1:8; 2:10,11; 3:10; 4:12; 5:12 |
| tofacitinib | 4:6-11 |
| transepidermal water loss | 1:5 |
| Tremfya® | 4:12 |
| trifarotene | 1:8; 2:1-2 |
| truncal acne | 2:1-2 |
| tryptophan | 5:8 |
| tumor necrosis factor-alpha | 1:8; 2:10,11; 3:10; 4:12; 5:12 |
U | |
| ultraviolet radiation damage | 2:7 |
| upadacitinib | 4:7 |
| urticaria | 1:8; 2:11 |
| ustekinumab | 5:12 |
| uveitis | 5:3 |
V | |
| vaccine | 2:11 |
| vasculitides | 3:5-9 |
| vemurafenib | 5:12 |
| vitamin B3 | 5:8-11 |
| vitamin D | 2:11; 5:12 |
| vitiligo | 4:6-11 |
W | |
| Winlevi® | 5:12 |
| Wynzora® | 5:12 |
X | |
| Xeglyze™ | 5:12 |
| X-linked hypohidrotic ectodermal dysplasia | 4:12 |
Y | |
Z | |
| Zelboraf® | 5:12 |
| Zilxi™ | 4:12 |
